Navigation Links
National Stem Cell Holding, Inc. to Present Keynote Address at The Stem Cell Partnering Series Inaugural Meeting in San Diego
Date:2/26/2008

Tuesday February 26, 2008 9:15 am ET

MOUNTAINSIDE, N.J., Feb. 26 /PRNewswire-FirstCall/ -- National Stem Cell Holding, Inc. (Pink Sheets: NHGI) today announced that its President Michael Cohen will present a Keynote Address, "A New Collaboration Model for Government Agencies, Academic Institutions and Development Stage Biotech Companies," at the Inaugural meeting of The Stem Cell Partnering Series: Fostering Business Collaborations & Careers in Stem Cell Science, February 28- 29, 2008, to be held at the University of California San Diego.

National Stem Cell President, Michael Cohen, stated, "I am pleased to participate in this event which has focused much needed attention to two critically important issues facing the stem cell / Regenerative Medicine industry: the need for increasing and improving strategic collaborations among the key stakeholders namely, development stage biotech companies, academic Institutions and government agencies, together with the attendant need to develop and recruit trained scientific personnel to meet both current and future industrial demands. Failure to address these issues rapidly and effectively within the U.S. risks the significant loss of intellectual property research and development and value to industrial sectors abroad."

The Stem Cell Partnering Series is a not-for-profit organization that actively supports the development and sustainability of the stem cell industry by fostering business collaborations and career development.

For more information on National Stem Cell Holding, Inc. please contact us at the company website: http://www.nationalstemcell.com or http://www.pinksheets.com.

About National Stem Cell Holding, Inc.

National Stem Cell Holding, Inc. is a hybrid biotechnology company focused on developing therapeutics based upon the use of human stem cells and their derivatives. The term 'hybrid' refers to both the business model as well its product line. The Company is developing a pipeline of proprietary stem cell therapeutics with particular focus on diabetes. Many of the currently incurable diseases associated with aging are caused by the degeneration of specific cell types in the body. These include but are not limited to: cancer, heart disease, diabetes, neurodegenerative diseases and auto immune conditions. In addition to its work with stem cell therapeutics, the Company is leveraging its commercial infrastructure and product development capabilities of its wholly-owned subsidiaries The Sperm Bank of NY (tissue Bank and IVF laboratory) and National Stem Cell Blood Laboratories Inc (cord blood banking program), and its affiliate, Decouverte Cosmetique, Inc. (cosmetics). The Company's investigational products are focused on the improvement of the quality of life for patients and their families. The Company's multi-facetted R&D program has demonstrated results with over 10 patent applications and multiple products ready to enter the market. The Company is headquartered in Mountainside, NJ and has facilities at multiple academic institutions.

"Safe Harbor Statement"

Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The results anticipated by any or all of these forward-looking statements may not occur. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.

Contact:

Michael Cohen

Phone: (212)792-6188

ir@nationalstemcell.com


'/>"/>
SOURCE National Stem Cell Holding, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. International Confocal Microscopy Working Group Established to Advance Practice of Reflective Confocal Microscopy
2. Bio-Clean International, Inc. to Present at Bluechip Capital Investment Forum
3. QED International Associates Announces Changes to the HealthShares(TM) Dermatology and Wound Care Index
4. IBF Conferences Inc., (International Business Forum) and BioEnterprise Present the 2nd Annual Global Healthcare Investing Conference
5. National Stem Cell Holding, Inc. Has Engaged BMA Securities to Assist and Advise the Company With Its Current Capital Raise of $3,500,000
6. National Fire Protection Association (NFPA) Sets New National Standard for CO Screening by Pulse CO-Oximetry(TM)
7. National Nanotechnology Initiative releases its fiscal year 2009 budget and highlights
8. Addressing the Pharmacist Shortage: Medco Labor Coalition(TM) Launches National Scholarship Program to Support the Development of the Next Generation of Pharmacists
9. Siemens and National Jewish Medical and Research Center Form Strategic Alliance to Advance Shared Vision of Personalized Medicine
10. National Public Radio (NPR) Features Broadcast Articles on NanoLogix Hydrogen Bioreactor Operation at Welchs Foods
11. PAREXEL International Announces 2-For-1 Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Benchworks ... March 22 in Philadelphia. The event was offered by the Chamber of Commerce ... featured breakout groups and interaction with speakers who are leaders in their ...
(Date:3/28/2017)... LONDON , March 28, 2017 ... to better understand Enzo Biochem and its partnering interests and ... since 2010 report provides an in-depth insight into the partnering ... On demand company reports are prepared upon purchase ... and company data. The report will be delivered ...
(Date:3/28/2017)... -- The National Pharmaceutical Council (NPC) today announced that Ipsen ... as its newest member. David Cox , PhD, ... America ), will serve as his company,s representative ... to have Ipsen and Dr. Cox join NPC as ... welcome their insights in helping us identify and address ...
(Date:3/28/2017)... , March 28, 2017 Biostage, ... biotechnology company developing bioengineered organ implants to treat cancers ... trachea, today announced that Jim McGorry, CEO ... and BioEngineering panel at the MassBio 2017 ... 2:30 PM ET in Cambrige, Massachussetts. The 3D ...
Breaking Biology Technology:
(Date:3/9/2017)... March 9, 2017 4Dx has publicly released ... Imaging Workshop at the University of Pennsylvania. Founder and ... deliver the latest data to world leaders in lung ... together leaders at the forefront of the industry to ... "The quality of the imaging is ...
(Date:3/2/2017)... YORK , March 2, 2017 Summary ... better understand Perrigo and its partnering interests and activities since ... ... Partnering Deals and Alliance since 2010 report provides an in-depth ... leading life sciences companies. On demand company reports ...
(Date:2/28/2017)... Feb. 28, 2017   Acuant , a leading ... announces significant enhancements to new and core technologies building ... products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity documents ... provides the fastest and most accurate capture software to ...
Breaking Biology News(10 mins):